Literature DB >> 11796598

Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis.

Lise Brandt1, Joana Feino Cunha, Anja Weinreich Olsen, Ben Chilima, Penny Hirsch, Rui Appelberg, Peter Andersen.   

Abstract

The efficacy of Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine against pulmonary tuberculosis (TB) varies enormously in different populations. The prevailing hypothesis attributes this variation to interactions between the vaccine and mycobacteria common in the environment, but the precise mechanism has so far not been clarified. Our study demonstrates that prior exposure to live environmental mycobacteria can result in a broad immune response that is recalled rapidly after BCG vaccination and controls the multiplication of the vaccine. In these sensitized mice, BCG elicits only a transient immune response with a low frequency of mycobacterium-specific cells and no protective immunity against TB. In contrast, the efficacy of TB subunit vaccines was unaffected by prior exposure to environmental mycobacteria. Six different isolates from soil and sputum samples from Karonga district in Northern Malawi (a region in which BCG vaccination has no effect against pulmonary TB) were investigated in the mouse model, and two strains of the Mycobacterium avium complex were found to block BCG activity completely.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796598      PMCID: PMC127715          DOI: 10.1128/IAI.70.2.672-678.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

Review 1.  Tuberculosis vaccines: developmental work and the future.

Authors:  T M Doherty; P Andersen
Journal:  Curr Opin Pulm Med       Date:  2000-05       Impact factor: 3.155

2.  The case for B.C.G.

Authors:  S P Tripathy
Journal:  Ann Natl Acad Med Sci       Date:  1983 Jan-Mar

3.  T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. Evidence for different kinetics and recognition of a wide spectrum of protein antigens.

Authors:  I M Orme; E S Miller; A D Roberts; S K Furney; J P Griffin; K M Dobos; D Chi; B Rivoire; P J Brennan
Journal:  J Immunol       Date:  1992-01-01       Impact factor: 5.422

4.  Importance of thymus-derived lymphocytes in cell-mediated immunity to infection.

Authors:  R J North
Journal:  Cell Immunol       Date:  1973-04       Impact factor: 4.868

5.  Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction?

Authors:  F A al-Kassimi; M S al-Hajjaj; I O al-Orainey; E A Bamgboye
Journal:  Am J Respir Crit Care Med       Date:  1995-11       Impact factor: 21.405

6.  How environmental mycobacteria may predetermine the protective efficacy of BCG.

Authors:  J L Stanford; M J Shield; G A Rook
Journal:  Tubercle       Date:  1981-03

7.  Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis.

Authors:  C E Palmer; M W Long
Journal:  Am Rev Respir Dis       Date:  1966-10

8.  BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life.

Authors:  P D Hart; I Sutherland
Journal:  Br Med J       Date:  1977-07-30

9.  The effect of two distinct forms of cell-mediated response to mycobacteria on the protective efficacy of BCG.

Authors:  G A Rook; G M Bahr; J L Stanford
Journal:  Tubercle       Date:  1981-03

10.  Evaluation of the effectiveness of BCG vaccination using the case-control method in Buenos Aires, Argentina.

Authors:  I Miceli; I N de Kantor; D Colaiácovo; G Peluffo; I Cutillo; R Gorra; R Botta; S Hom; H G ten Dam
Journal:  Int J Epidemiol       Date:  1988-09       Impact factor: 7.196

View more
  142 in total

1.  Deletion of Mycobacterium tuberculosis sigma factor E results in delayed time to death with bacterial persistence in the lungs of aerosol-infected mice.

Authors:  Masaru Ando; Tetsuyuki Yoshimatsu; Chiew Ko; Paul J Converse; William R Bishai
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

2.  Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model.

Authors:  Anja W Olsen; Ann Williams; Limei M Okkels; Graham Hatch; Peter Andersen
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

3.  A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.

Authors:  Thomas J Scriba; Michele Tameris; Erica Smit; Linda van der Merwe; E Jane Hughes; Blessing Kadira; Katya Mauff; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Humphrey Mulenga; Marwou de Kock; Lebohang Makhethe; Esme Janse van Rensburg; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Hendrik Geldenhuys; Adrian V S Hill; Anthony Hawkridge; Gregory D Hussey; Willem A Hanekom; Helen McShane; Hassan Mahomed
Journal:  Am J Respir Crit Care Med       Date:  2012-01-26       Impact factor: 21.405

4.  Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.

Authors:  Vasan K Sambandamurthy; Steven C Derrick; Kripa V Jalapathy; Bing Chen; Robert G Russell; Sheldon L Morris; William R Jacobs
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 5.  Recent Trends in System-Scale Integrative Approaches for Discovering Protective Antigens Against Mycobacterial Pathogens.

Authors:  Aarti Rana; Shweta Thakur; Girish Kumar; Yusuf Akhter
Journal:  Front Genet       Date:  2018-11-27       Impact factor: 4.599

Review 6.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

7.  Prevalence and associated risk factors of mycobacterial infections in slaughter pigs from Mubende district in Uganda.

Authors:  Adrian Muwonge; Clovice Kankya; Jacques Godfroid; Berit Djonne; John Opuda-Asibo; Demelash Biffa; Takele Ayanaw; Musso Munyeme; Eystein Skjerve
Journal:  Trop Anim Health Prod       Date:  2009-12-12       Impact factor: 1.559

8.  What has Karonga taught us? Tuberculosis studied over three decades.

Authors:  A C Crampin; J R Glynn; P E M Fine
Journal:  Int J Tuberc Lung Dis       Date:  2009-02       Impact factor: 2.373

9.  Gammadelta T cells in immunity induced by Mycobacterium bovis bacillus Calmette-Guérin vaccination.

Authors:  Jinhee Lee; Keumhwa Choi; Michael R Olin; Sang-Nae Cho; Thomas W Molitor
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

10.  Attenuation of late-stage disease in mice infected by the Mycobacterium tuberculosis mutant lacking the SigF alternate sigma factor and identification of SigF-dependent genes by microarray analysis.

Authors:  Deborah E Geiman; Deepak Kaushal; Chiew Ko; Sandeep Tyagi; Yukari C Manabe; Benjamin G Schroeder; Robert D Fleischmann; Norman E Morrison; Paul J Converse; Ping Chen; William R Bishai
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.